Loading
Axsome Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Sept 2025.
Axsome Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Axsome Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in New York City, United States. It was founded in 2012. Between 18 October 2025 and 18 October 2026, 14 insiders published 54 filings.
All open-market trades in the period are sales: 18 sales worth €19.9M, by 7 insiders, with no purchase on record. No amount is published for 8 filings, which the totals therefore leave out. Tabuteau Herriot filed the largest sale, €8.3M, on 7 August 2026, which represents 0.092% of the company's market value.
Compared with its exchange (5,816 companies, median 19 filings), a count of 54 filings is above the norm. The full history, which starts in 2021, counts 8 purchases against 33 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 638.5 m USD and net income of -183.2 m USD.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
99
Thresholds
n/a
Buy Volume
€444,720
8 ops. · all time
Sell Volume
€42M
33 ops. · all time
Who traded when
BuySaleColeman Mark3 buys8 sales
Herriot Tabuteau7 sales
Mark L. Jacobson7 sales
Jeffs Roger6 sales
Mahony Susan2 sales
Maizel Ari1 sale
+1 other insider
Since the insiders bought
- +70.1%Entry US$124.12 · Close at T+365 US$211.12
- +49.8%Entry US$37.93 · Close at T+365 US$56.82
- +53.6%Entry US$36.59 · Close at T+365 US$56.22
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Axsome Therapeutics, Inc. Strong Buy (bullish), based on 22 analysts. Average price target: US$282.54.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,114 of 24,148 companies
31.5
score / 100
Value29
Quality34
FCF yld-1.1%
Earn yld-2.2%
EV/EBITDA·
ROE-245%
Gross mgn93%
Net mgn-29%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$161.79
Analyst consensus
22 analystsStrong buy
US$245.00Target US$282.54(+75%)US$380.00
Income statement
RevenueUS$638.5M
Gross profitUS$591M93% margin
EBITDA-US$168.1M-26% margin
Net income-US$183.2M-24.7% margin
Valuation
PER (forward)40.1x
P/Book101.6x
Beta0.85
Balance sheet & cash
Market capUS$8.5B
Total debtUS$218.1M
Free Cash Flow-US$93.9M
Debt / Equity270%
Profitability & ownership
ROE-245.1%
ROA-16.3%
% insiders15.1%
% institutions74.7%
Last declaration on 3 September 2026
Declarations99 total
10,000 shares@ US$12.950.0012% mcap1.1% of flowCommon StockSEC:0001193125-26-382277:0
10,000 shares@ US$208.650.020% mcap17.4% of flowCommon StockSEC:0001193125-26-382277:1
10,000 shares@ US$208.350.020% mcap100.0% of flowClass A CommonSEC144:0001958244-26-000571
4,660 shares@ US$213.950.0096% mcap4.8% of flowCommon StockSEC:0001193125-26-340688:3
45,004 shares@ US$4.950.0022% mcap1.1% of flowCommon StockSEC:0001193125-26-340688:0
45,004 shares@ US$212.010.092% mcap46.2% of flowCommon StockSEC:0001193125-26-340688:1
4,660 shares@ US$4.950.0002% mcap0.1% of flowCommon StockSEC:0001193125-26-340688:2
4,660 shares@ US$210.130.0094% mcap2.8% of flowCommon StockSEC144:0001958244-26-000491
45,004 shares@ US$212.850.093% mcap27.5% of flowCommon StockSEC144:0001958244-26-000488
49,666 shares@ US$240.660.12% mcap34.7% of flowCommon StockSEC144:0001958244-26-000417
49,666 sharesCommon StockSEC:0001193125-26-292985:0
49,666 sharesCommon StockSEC:0001193125-26-292985:1
286 shares@ US$249.11890.0006% mcap0.8% of flowCommonSEC144:0001921094-26-000636
286 sharesCommon StockSEC:0001193125-26-268202:0
286 sharesCommon StockSEC:0001193125-26-268202:1
643 shares@ US$249.00310.0013% mcap1.4% of flowCommonSEC144:0001921094-26-000631
286 shares@ US$246.17830.0006% mcap0.8% of flowCommonSEC144:0001921094-26-000632
300 shares@ US$246.180.0006% mcap50.9% of flowCommonSEC144:0001921094-26-000633
1,429 sharesCommon StockSEC:0001193125-26-266433:0
643 sharesCommon StockSEC:0001193125-26-266433:1
1,429 sharesCommon StockSEC:0001193125-26-266435:0
300 sharesCommon StockSEC:0001193125-26-266435:1
300 sharesCommon StockSEC:0001193125-26-266435:2
1,429 sharesCommon StockSEC:0001193125-26-266436:0
1,429 sharesCommon StockSEC:0001193125-26-266437:0
25 of 99 declarations
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, a therapeutic area that remains both clinically challenging and commercially attractive because of persistent unmet medical need. Founded in 2012, Axsome built its strategy around developing and commercializing differentiated treatments for psychiatric and neurological conditions. The company is listed on the NASDAQ under the ticker AXSM, and its corporate headquarters is in New York, United States. ([stockanalysis.com](https://stockanalysis.com/stocks/axsm/company/?utm_source=openai))
Axsome’s business model now combines marketed products with a late-stage CNS pipeline. Its core commercial assets include AUVELITY, approved for major depressive disorder in adults; SUNOSI, used to treat excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea; and SYMBRAVO, which received FDA approval in January 2025 for the acute treatment of migraine with or without aura in adults. The company also highlights its proprietary MoSEIC technology for selected formulations and positions its portfolio around multi-mechanistic approaches intended to address complex CNS symptoms. ([stockanalysis.com](https://stockanalysis.com/stocks/axsm/company/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Axsome operates in highly contested markets dominated by large pharmaceutical companies as well as neuroscience-focused specialists. Its differentiation rests on product innovation, clinical execution, and the gradual expansion of its marketed portfolio. Axsome describes itself as targeting treatment gaps in conditions where existing options are limited, which can support a premium positioning if physician adoption and payer access continue to improve. ([axsome.com](https://www.axsome.com/about-axsome/))
Geographically, the company remains primarily U.S.-centric. Its commercial footprint, revenue generation, and major regulatory interactions are largely tied to the United States, although some SEC filings reference entities and agreements related to non-U.S. rights or structures. For investors, the practical operating base is still overwhelmingly American. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1579428/000095017025058788/axsm_fy2024_ars.pdf))
Recent developments are important for the investment case. In January 2025, the FDA approved SYMBRAVO, and Axsome said it was preparing a commercial launch beginning in June 2025. The company also reported progress on AXS-05 in Alzheimer’s disease agitation, including positive pre-NDA interactions with the FDA in March 2025 and plans for a supplemental NDA filing. In parallel, Axsome has continued to expand its sales force and strengthen its commercial infrastructure around AUVELITY and SUNOSI. Taken together, these milestones reinforce Axsome’s profile as a NASDAQ-listed U.S. neuroscience growth company transitioning from development-heavy execution toward a more diversified commercial platform. ([axsometherapeuticsinc.gcs-web.com](https://axsometherapeuticsinc.gcs-web.com/node/12031/pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
